| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Fairmount Funds Management LLC | Director, 10%+ Owner | 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN | /s/ Tomas Kiselak, Managing Member of Fairmount Funds Management LLC | 12 Feb 2026 | 0001802528 |
| Fairmount Healthcare Fund II L.P. | 10%+ Owner | 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN | /s/ Tomas Kiselak, Managing Member of Fairmount Healthcare Fund II L.P. | 12 Feb 2026 | 0001769651 |
| Fairmount Healthcare Co-Invest V L.P. | 10%+ Owner | 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN | /s/ Tomas Kiselak, Managing Member of Fairmount Healthcare Co-Invest V L.P. | 12 Feb 2026 | 0002091559 |
| Kiselak Tomas | 10%+ Owner | 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN | /s/ Tomas Kiselak | 12 Feb 2026 | 0001830177 |
| Harwin Peter Evan | Director, 10%+ Owner | 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN | /s/ Peter Harwin | 12 Feb 2026 | 0001663607 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | GLTO | Common Stock | Options Exercise | $0 | +5,809,000 | $0.000000 | 5,809,000 | 09 Feb 2026 | By Fairmount Healthcare Fund II L.P. | F1, F2, F3 | |
| transaction | GLTO | Common Stock | Options Exercise | $0 | +2,904,000 | $0.000000 | 2,904,000 | 09 Feb 2026 | By Fairmount Healthcare Co-Invest V L.P. | F1, F2, F3 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | GLTO | Series C Preferred Stock | Options Exercise | $0 | -5,809 | -83% | $0.000000 | 1,148 | 09 Feb 2026 | Common Stock | 5,809,000 | By Fairmount Healthcare Fund II L.P. | F1, F2, F3, F4 | |
| transaction | GLTO | Series C Preferred Stock | Options Exercise | $0 | -2,904 | -83% | $0.000000 | 574 | 09 Feb 2026 | Common Stock | 2,904,000 | By Fairmount Healthcare Co-Invest V L.P. | F1, F2, F3, F4 |
| Id | Content |
|---|---|
| F1 | On February 9, 2026, the Issuer's stockholders approved the issuance of Common Stock upon conversion of the Issuer's Series C Non-Voting Convertible Preferred Stock, par value $0.00001 per share ("Series C Preferred Stock") (the "Requisite Stockholder Approval"). Accordingly, pursuant to the terms of the Certificate of Designations of Preferences, Rights and Limitations of Series C Non-Voting Convertible Preferred Stock, 5,809 shares of Series C Preferred Stock held by Fairmount Healthcare Fund II LP ("Fund II") and 2,904 shares of Series C Preferred Stock held by Fairmount Healthcare Co-Invest V L.P. ("Co-Invest") were converted into 5,809,000 shares of Common Stock and 2,904,000 shares of Common Stock, respectively. The securities of the Issuer held by the Reporting Persons, including the shares of Common Stock received upon conversion of the Series C Preferred Stock, are subject to the terms a lock-up agreement entered into with the underwriters for the Issuer's public offering, |
| F2 | (Continued from footnote 1) pursuant to which certain of the Reporting Persons agreed, subject to certain exceptions, not to directly or indirectly sell or otherwise transfer securities of the Issuer for a period of 60 days following the date of the final prospectus supplement relating to the public offering, which was February 10, 2026. |
| F3 | Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fund II and Co-Invest. Peter Harwin and Tomas Kiselak are the managers of Fairmount. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. |
| F4 | Following receipt of the Requisite Stockholder Approval, each share of Series C Preferred Stock automatically converted into 1,000 shares of Common Stock, subject to certain beneficial ownership limitations. The Series C Preferred Stock has no expiration date. Fairmount may not convert such shares if Fairmount, together with its affiliates, would beneficially own more than 19.99% of the number of shares of Common Stock outstanding immediately after giving effect to such conversion. |
Fairmount, Fund II and Co-Invest may each be deemed a director by deputization of the Issuer by virtue of the fact that Peter Harwin serves on the board of directors of the Issuer and is a manager of Fairmount.